E C Rizos, H J Milionis, M S Elisaf. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Administration, OralAntipruritics/therapeutic useBone Density Conservation Agents/adverse effectsDiphosphonates/adverse effectsDrug Therapy, CombinationExanthema/chemically inducedExanthema/drug therapyExanthema/pathologyFemaleFever/chemically inducedFever/drug therapyFever/pathologyGlucocorticoids/therapeutic useHumansImidazoles/adverse effectsInjections, IntravenousLoratadine/therapeutic useMiddle AgedOsteoporosis, Postmenopausal/drug therapyOsteoporosis, Postmenopausal/pathologyPrednisone/therapeutic useTreatment OutcomeZoledronic Acid
Substances: See more » AntipruriticsBone Density Conservation AgentsDiphosphonatesGlucocorticoidsImidazolesZoledronic AcidLoratadinePrednisone
Year: 2006 PMID: 16956442
Source DB: PubMed Journal: Clin Exp Rheumatol ISSN: 0392-856X Impact factor: 4.473